BP 1200
Alternative Names: BP-1200Latest Information Update: 05 Oct 2021
At a glance
- Originator BrightPath Biotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Oct 2021 BP 1200 is available for licensing as of 05 Oct 2021. https://www.brightpathbio.com
- 01 Oct 2021 Preclinical trials in Cancer in Japan (Parenteral) as of October 2021
- 16 Sep 2021 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 46th European Society for Medical Oncology Congress (ESMO-2021)